BAT's Glo Sees Strong Global Growth in 2022

Feb.16.2023
BAT's Glo Sees Strong Global Growth in 2022
BAT's 2022 report reveals Glo's growth: global market share of 19.4%, 24.3% revenue increase, and 30% growth in consumers.

Recently, British American Tobacco (BAT) released its 2022 annual report. The report disclosed operational data for BAT's Glo product in 2022.


Report Reveals Global Market Outlook for Glo in 2022:


Glo's market share has reached 19.4%, a year-on-year increase of 1.4%. Glo's global revenue has grown by 24.3% or 26.7% and is expected to continue to grow in the second half of 2022. The number of Glo's consumers has increased by 2 million, reaching 8.8 million, a growth of 30%. Glopod's sales have grown by 25.6%, surpassing the industry growth rate of 15%. Glo's share of the tobacco market (FMC and THP combined) has reached 7.4%, an increase of 0.6% compared to 2021.


In 2022, Glo's sales performance in its key markets is as follows:


Glo, a tobacco heating product (THP) produced by British American Tobacco (BAT), has seen an increase in its market share in Japan and Europe. In Japan, a shift in consumer preference from traditional cigarettes to THPs has boosted Glo's market share (combining both traditional tobacco and THPs) to 7.4% in 2021, representing a 0.6% growth from the previous year. Meanwhile, in Europe, Glo's sales have grown by 33.8% leading to a continued strong increase in revenue by 57.3% or 53.3% (at a fixed exchange rate). The region currently accounts for over 54% of BAT's global THP volume (excluding Russia, which accounts for 43%) and 51% of BAT's global THP revenue (excluding Russia, which is 41%). Sources:


A new category acceleration will boost profitability until 2024.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
Proposed vaping duty in Jersey: £467,000 forecast for 2026 as it takes effect in the second half of the year
Proposed vaping duty in Jersey: £467,000 forecast for 2026 as it takes effect in the second half of the year
Jersey is proposing a vaping duty. The Treasury Minister said the duty is forecast to raise £467,000 in 2026 because it will take effect in the second half of the year, and £955,000 per year from 2027 to 2029. Implementation is estimated to cost around £400,000 over four years, with an initial cost of £145,000 in 2026. The policy is described as aiming to reduce nicotine consumption and improve public health, while avoiding a shift to smoking.
Feb.26 by 2FIRSTS.ai
USITC Issues Final Ruling in 337-TA-1392 Investigation, Imposes Limited Exclusion Order and Cease and Desist Orders
USITC Issues Final Ruling in 337-TA-1392 Investigation, Imposes Limited Exclusion Order and Cease and Desist Orders
USITC issues final ruling on oil vaporizing devices, components violating tariff law, with limited exclusion order and cease-and-desist orders.
Jan.21 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Finland’s Ostrobothnia Police Seize Over 6,000 E-Cigarettes in Vaasa Raid, Probe Cross-Border Supply
Finland’s Ostrobothnia Police Seize Over 6,000 E-Cigarettes in Vaasa Raid, Probe Cross-Border Supply
According to a statement from Finland’s Ostrobothnia Police, officers seized more than 6,000 e-cigarettes during a home search in the Haapaniemi area of Vaasa in early January, after the case surfaced in connection with drug enforcement work.Police suspect the products were ordered from abroad for resale in Finland and were marketed and sold via Telegram.
Jan.29 by 2FIRSTS.ai
Special Report|Russia scales back anti-vaping drive, limits ban to single-region trial
Special Report|Russia scales back anti-vaping drive, limits ban to single-region trial
After months of debate, Russian lawmakers have retreated from plans for a nationwide vaping ban, opting instead for a single-region pilot. The shift reflects pressure from business groups and fiscal authorities, amid warnings that sweeping prohibitions could fuel illegal trade while undermining efforts to regulate the market.
Jan.22